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ABSTRACT: 
 
Background: Diabetic patients account for an increasing number of patients undergoing 
percutaneous coronary intervention (PCI). However, diabetes mellitus (DM) is associated 
with increased residual platelet activity during dual antiplatelet treatment (DAPT) and 
DM patients have worse clinical outcomes after PCI as compared to non-DM.  
Objective: To evaluate efficacy and safety of short duration DAPT (S-DAPT) and long 
duration DAPT (L-DAPT) after drug eluting stent (DES) implantation in DM and non-
DM patients.  
Methods: We searched Medline, Embase, and Cochrane Central Register of Controlled 
Trials (CENTRAL) to identify randomized controlled trials (RCTs) assessing the effect 
of S-DAPT versus L-DAPT after DES implantation in DM and non-DM patients. 
Efficacy endpoints were all-cause mortality, cardiac mortality, myocardial infarction 
(MI), stent thrombosis (ST), target vessel revascularization (TVR), and composite end 
point of net adverse clinical events (NACE) (all cause mortality, cardiac mortality, MI, 
ST, TVR, stroke, major bleeding). Safety endpoints were major bleeding and stroke. 
Event rates were compared using a forest plot of relative risk using a random effects 
model.  
Results: We included eight RCTs that randomized 28,318 patients to S-DAPT versus L- 
DAPT (8,234 DM and 20,084 non-DM).  S-DAPT was associated with an increased rate 
of ST in non-DM patients [3.67 (2.04, 6.59)]. There was no significant difference in the 
rate of all cause mortality, cardiac mortality, ST, MI, TVR, major bleeding, stroke and 
NACE with S-DAPT and L-DAPT in DM patients [1.19 (0.72-1.95); 1.25 (0.69, 2.25); 
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1.52 (0.70, 3.29); 1.33 (0.88, 2.01); 1.39 (0.89, 2.17); 0.92 (0.19, 4.42); 0.98 (0.29, 3.28); 
and 0.94 (0.57, 1.54) respectively]. Further, there was no significant difference in the rate 
of all cause mortality, cardiac mortality, MI, TVR, major bleeding, stroke and NACE 
with S-DAPT and L-DAPT in non-DM patients [0.93 (0.58, 1.48); 0.75 (0.42, 1.35); 1.52 
(0.81, 2.83); 0.99 (0.71, 1.39); 0.72 (0.28, 1.84); 1.01 (0.40, 2.56); and 1.01 (0.77, 1.32) 
respectively].  
Conclusion:  Compared to L-DAPT, S-DAPT was associated with significant increase in 
rate of ST in non-DM patients. Duration of DAPT had no significant impact on rates of 
all cause mortality, cardiac mortality, MI, ST and TVR among DM patients. 
 
Key Words: Dual anti-platelet therapy, Drug eluting stents, Diabetes   
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ABBREVIATIONS 
 
CAD: Coronary Artery Disease 
DAPT: Dual Anti-platelet Therapy 
DES: Drug Eluting Stent 
DM: Diabetes Mellitus 
L-DAPT: Long Dual Anti-platelet Therapy 
MI: Myocardial Infarction 
NACE: Net Adverse Cardiovascular Event 
PCI: Percutaneous Coronary Intervention 
RCT: Randomized Controlled Trial 
S-DAPT: Short Dual Anti-platelet Therapy 
ST: Stent Thrombosis 
TVR: Target Vessel Revascularization 
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INTRODUCTION: 
 
The prevalence of diabetes mellitus (DM) is increasing globally, and optimal care of DM 
patients remains a challenge for health care providers. Patients with DM have higher 
prevalence of coronary artery disease (CAD) and account for an increasing number of 
patients undergoing percutaneous coronary intervention (PCI) [1]. However, DM patients 
have worse clinical outcomes after PCI as compared to non-DM [1, 2].  
 
Dual antiplatelet therapy (DAPT) using a combination of aspirin and a P2Y12 inhibitor is 
used for the prevention of ischemic complications after PCI. However, the optimal 
duration of DAPT after drug-eluting stent(s) (DES) implantation remains unclear [3]. 
Several studies have reported an increase in bleeding complications with longer duration 
(>12 months) of DAPT (L-DAPT) compared to short duration (</=12 months) DAPT (S-
DAPT), without any significant improvement in the rates of atherothrombotic 
complications [4-10]. However, the large multicenter DAPT Study recently demonstrated 
improved clinical outcomes with longer duration of DAPT (L-DAPT) compared to short 
duration DAPT (S-DAPT) [11]. Pooled analyses of various randomized controlled trials 
(RCTs) have reported conflicting results [12-20]. Inconsistent results are likely due to the 
evaluation of different studies and patient subgroups. Diabetes mellitus is associated with 
a prothrombotic state secondary to endothelial dysfunction, hyper-coagulability, and 
platelet activation. Thus, the benefits of L-DAPT versus S-DAPT in diabetic patients 
warrant investigation. Against this background, we performed a meta-analysis of RCTs to 
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evaluate the efficacy and safety of S-DAPT and L-DAPT after DES implantation in DM 
and non-DM patients. 
 
METHODS: 
 
We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analyses) statement for reporting systematic reviews and meta-analyses of RCTs for the 
protocol of our meta-analysis [21]. 
 
We systematically searched PubMed, CINAHL, Cochran CENTRAL, Embase, Scopus 
and Web of Science databases for randomized clinical trials comparing different 
durations of DAPT after DES implantation in patients with and without DM. Pertinent 
trials were also searched in clinicaltrials.gov and in the proceedings of major 
international cardiology meetings (ACC, AHA, ESC, The Society for Cardiac 
Angiography and Interventions). In addition, the reference lists of the identified studies 
were searched for any potential relevant studies. DAPT was defined as aspirin plus a 
P2Y12 receptor inhibitor, after coronary DES implantation. S-DAPT and L-DAPT were 
defined as duration of DAPT after DES implantation </=12months and >12months 
respectively. All relevant combinations of following keywords  “aspirin”, “P2Y12 
receptor inhibitor “, “clopidogrel”, “Plavix”, “prasugrel”, “Effient”, “ticagrelor”, 
“Brilinta”, “thienopyridine”, “dual antiplatelet therapy”, “DAPT”, “drug eluting stents”, 
“DES”, “diabetes mellitus”, “DM”, “non diabetics”, “non DM”, “death”, “mortality”, 
“survival”, “cardiac mortality”, “stent thrombosis”, “Global Utilization Of Streptokinase 
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And Tpa For Occluded Arteries (GUSTO) bleeding”, stroke, myocardial infarction, 
“randomized controlled trial”, “random”, “random allocation”, “double-blind”, and 
“single-blind” were included for database search. We manually searched references of 
identified studies. Only studies published between January 1, 2002 to June 30, 2016 were 
included. No language restrictions were applied. Studies, which did not report the 
absolute numbers of events in DM and non-DM patients after DES implantation, were 
excluded from the analysis. The corresponding authors of the relevant studies were 
queried for required quantitative details not in the published manuscripts. 
 
Two reviewers (AS, AG) independently screened the titles and abstracts for relevance. 
The full texts of selected manuscripts were reviewed for inclusion or exclusion using the 
above mentioned selection criteria. Two reviewers (AS, AG) independently determined 
the articles to be included and excluded, and data from the relevant articles were 
extracted using pre-defined extraction forms.  Any disagreements in data extraction were 
discussed until consensus was reached. Baseline patient characteristics and follow up data 
was extracted from selected studies at the end of follow up period: all-cause mortality, 
cardiac mortality, myocardial infarction (MI), stent thrombosis (ST), target vessel 
revascularization (TVR), major bleeding, stroke and net adverse cardiovascular event 
(NACE), the composite of all cause mortality, cardiac mortality, MI, ST, TVR, stroke, 
major bleeding. MI and major bleeding was defined per trial definition. ST was defined 
as per Academic Research Consortium (ARC) [22].  
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The statistical analysis was performed according to the recommendations from the 
Cochrane Collaboration using Review Manager Version 5.1 (The Nordic Cochrane 
Center, The Cochrane Collaboration, 2008, Copenhagen). A random-effects model with 
inverse variance weighting was used to calculate odds ratio (OR) and 95% confidence 
interval, associated with S-DAPT versus L-DAPT for above end points. Forest plots were 
used to observe the overall effect of studies for each endpoint. Heterogeneity between 
studies was assessed using Cochrane’s Q test and I2 statistic, which denotes the 
percentage of total variation across studies that is a result of heterogeneity rather than 
chance. I
2
 < 25 % was considered as low heterogeneity and I
2
 > 75 % as high. 
Heterogeneity was considered significant if the p value was less than 0.05. Publication 
bias was assessed by Begg’s test and Egger’s regression test.  
 
 
RESULTS: 
 
2819 publications were found at initial search and after abstract and manuscript 
evaluation eight studies are selected for final analysis (Figure 1). Investigators of 
OPTIMIZE and OPTIDUAL trials have shared their data on outcomes for DM and non-
DM patients after PCI for this analysis, which was not reported/published before [5, 8]. 
In the selected eight RCTs, 28,318 patients were randomized to S-DAPT (N=14,095) 
versus L-DAPT (14, 203) (Table 1) [4-11]. Out of 28,318 patients 8,234 had DM and 
20,084 were non-diabetics. Median follow up period in studies included in our analysis 
varied from 9 months to 33 months with overall median follow up of 12 months after 
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completion of L-DAPT. Use of second generation DES varied from 36% to 100%. 
Baseline characteristics of patients and studies included in the final analysis are 
summarized in Table 2. 
 
On analysis, of 18025 patients (5417 DM and 12608 non-DM),  S-DAPT was associated 
with an increased rate of ST in non-DM patients [3.67 (2.04, 6.59), p<0.0001] (Figure2). 
There was  no significant difference in the rate of ST with S-DAPT among DM patients 
[1.52 (0.70, 3.29), p=0.29] (Figure2) (Table 3). There was borderline interaction between 
subgroups for ST (Pinteraction=0.07). Overall, regardless of DAPT duration, DM patients have 
higher rates of ST (0.72%) than non-DM patients (0. 57%). There was also no significant 
difference in the rate of MI with S-DAPT and L-DAPT in DM [1.33 (0.88, 2.01), p=0.18] 
and non-DM [1.52 (0.81, 2.83), p=0.19] patients on analysis of 18025 patients (5417 DM 
and 12608 non-DM) (Figure 3) (Table 3). DM patients have higher rates of MI (3.30%) 
than non-DM (2.08%) irrespective of the duration of DAPT. 
 
There was also no significant difference in the rate of all cause mortality, and cardiac 
mortality with S-DAPT and L-DAPT in DM [1.19 (0.72-1.95) and 1.25 (0.69, 2.25) 
respectively] and non-DM-patients [0.93 (0.58, 1.48); and 0.75 (0.42, 1.35) respectively] 
(Figure 4, 5) (Table 3).  However, overall event rates of both all-cause mortality (3.16% 
vs 1.89%), and cardiac mortality (2.01% vs 0.83%) were higher for DM patients as 
compared to non-DM patients.  
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Similarly, no significant difference was found between S-DAPT and L-DAPT for TVR, 
major bleeding and stroke for DM [1.39 (0.89, 2.17); 0.92 (0.19, 4.42); and 0.98 (0.29, 
3.28) respectively] and non-DM patients [0.99 (0.71, 1.39); 0.72 (0.28, 1.84); and 1.01 
(0.40, 2.56) respectively] (Supplementary Figure 1, 2, 3) (Table 3).  On analysis of 
16,980 patients  (4762 with DM and 12218 non-DM patients) there was no significant 
difference in the rate of composite end point-NACE with S-DAPT and L-DAPT for DM 
[0.94 (0.57, 1.54)] and non-DM patients [1.01 (0.77, 1.32)] (Supplementary figure 4). 
However, overall event rates were higher among DM patients compared to non-DM 
(4.49% vs 3.01%). 
 
DISCUSSION: 
 
In our meta-analysis of RCTs in which patients were analyzed according to DM status, S-
DAPT compared to L-DAPT was associated with a significant increase in rate of ST in 
non-DM patients. However, there was no significant difference in the rate of all cause 
mortality, cardiac mortality, MI, ST and TVR with S-DAPT among DM patients. 
 
Although widespread use of DES has improved overall clinical outcomes [23, 24], 
sustained risk of ST and MI remain a major concern in DM patients [25-27]. This 
elevated risk has been partly attributed to existence of a pro-thrombotic state in DM 
patients secondary to several factors, including endothelial dysfunction, hyper-
coagulation and platelet hyperactivation [28, 29]. Furthermore, patients with impaired 
glucose metabolism have been reported to have a suboptimal biochemical response to 
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aspirin (a mainstay agent for DAPT)—‘aspirin resistance’ [30, 31]. Possible causes of 
this suboptimal response have been proposed including aspirin formulation used and dose 
of aspirin given [32]. Recently, in a randomized, single-blind, triple-crossover study 
Bhatt et al, investigated if suboptimal response to aspirin in diabetic patients is mediated 
via decrease oral bioavailability [33]. Forty patients with type 2 DM and without 
cardiovascular disease were randomized to receive a plain aspirin tablet, a PL2200 
aspirin capsule (modified-release lipid-based aspirin), and a delayed-release enteric-
coated (EC) aspirin caplet. There was no significant difference in aspirin response 
between plain aspirin and PL2200 aspirin (p=0.41), whereas aspirin response was quicker 
with the former two when compared to EC aspirin (p<0.001). The patients on EC aspirin 
were found to have lower levels of plasma aspirin, secondary to decreased absorption. 
Therefore, use of non-EC aspirin formulation might be more appropriate in this patient 
population. 
  
DAPT has been shown to be protective against early and late ischemic events after DES 
implantation, although the optimal duration remains unclear [12-20]. Even though DM 
patients have higher prevalence of CAD and they undergo coronary revascularization 
procedures, including PCI, more often than non-DM patients, there is paucity of data 
evaluating the impact of DM on duration of DAPT [34]. DM has been considered an 
independent variable in DAPT score, presence of which might favor L-DAPT after PCI 
[35]. However, in recent patient-level pooled analysis of 11,473 patients, Gargiulo and 
colleagues have reported that L-DAPT was associated with increased bleeding 
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complications in both DM and non-DM patients, without significant reduction in 
ischemic events [36]. 
 
In this context, our meta-analysis of RCTs provides important insights into relationship 
of DAPT duration with clinical outcomes among DM and non-DM patients after 
implantation of DES. Our results suggest that DM patients have higher rate of adverse 
CV events than non-DM patients after PCI with DES implantation irrespective of DAPT 
duration. Further, L-DAPT compared to S-DAPT might not be effective in reducing 
adverse cardiovascular outcomes after PCI in DM patients.  
 
While placing our results in the context of above findings, several points are worth 
mentioning. First, accelerated neointimal hyperplasia leading to endothelialization may 
account for the differential effect of prolonged DAPT on ST in patients with DM [37, 
38]. Second, diminished impact of antiplatelet agents in DM, especially clopidogrel, on 
platelet inhibition may explain a higher incidence of ST in the first 6 months, as seen in 
S-DAPT arm of EXCELLENT trial, where the reported ST events occurred while the 
patients were still on DAPT [7, 39]. Third, platelet hyper-reactivity has been implicated 
as a cause of increased thrombogenesis in DM, suggesting a place for more potent anti-
platelets [40, 41]. Although, relatively low number of events and inclusion of studies with 
short-term follow up [7, 10] precludes definitive conclusions, our results suggest complex 
interaction of various clinical end points and DM after DES implantation. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
DM has been shown to be an independent risk factor for ST [42]. One of the major issues 
surrounding DAPT duration is a sustained risk of late (1-12 months) [43] and very late 
(>12 months) ST [44] after DES implantation. Several medium-sized RCTs have shown 
that S- DAPT is non-inferior to L- DAPT in terms of incidence of ST [5, 6, 10], however 
these studies did not possess sufficient statistical power to assess ST. The Dual 
Antiplatelet Therapy (DAPT) study, the only study adequately powered for assessing 
DAPT duration on rates of ST, randomized event-free patients at 12 months to placebo 
versus extended (30 months) duration of DAPT and found a significantly reduced risk of 
ST with the L-DAPT (0.4% vs 1.4%, p <0.001) [22]. However, consistent with our 
finding, the protective effect of L-DAPT in DAPT trial was attenuated in DM patients 
(0.6% vs 1.1%), compared to non -DM (0.3% vs 1.5%) [11]. Similarly, in analysis of the 
diabetic subgroup of the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to 
Reduce Late Loss After Stenting) trial, there was trend toward increased risk of ST with 
S-DAPT when compared with standard 12-month DAPT [7]. Our analysis demonstrated 
significantly increased risk of ST with S-DAPT relative to L-DAPT in non-diabetic 
patients. Although in DM patients there was no statistically significant difference in the 
rate of ST with L-DAPT as compared to S-DAPT. This could be partly due to relatively 
small number of patients and events in the DM arm (5417 patients and 39 ST) compared 
to non-DM (12608 patients and 72 ST). This could be due to higher baseline platelet 
activity in DM patients, which remains higher than non-DM even after DAPT. 
 
Our analysis has several limitations. First, this is a meta-analysis performed on study-
level data due to non-availability of patient-level data. Thus, covariate-adjusted analyses 
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for possible confounders like generation of DES, clinical presentation/indication of PCI, 
location and complexity of lesions during PCI, baseline clinical characteristics (e.g. 
insulin dependent or non-insulin dependent DM, renal dysfunction, heart failure) could 
not be performed. Similarly, due to lack of patient-level information regarding use of 
statins, beta-blockers or renin–angiotensin system blockers, we could not evaluate their 
impact on the relative efficacy of prolonged DAPT in DM and non-DM patients. Studies 
included in our meta-analysis randomized patients with various clinical presentations and 
characteristics, thus it is unlikely that these variables would have confounded our results 
due to selection bias; however, this cannot be completely excluded on the basis of current 
analysis. Second, prasugrel and ticagrelor have been shown to be associated with 
decrease in the rate of ST compared to clopidogrel and have recently been recommended 
by the American College of Cardiology/American Heart Association and European 
Society of Cardiology for management of ACS [45, 46]. In the present study, we were 
unable to evaluate duration of DAPT with prasugrel and ticagrelor, as studies included in 
our analysis did not compare duration of DAPT using these antiplatelets separately. 
However, such variations in DAPT reflect real world clinical practice, where different 
second antiplatelet agents are selected based on operator choices, clinical settings and 
drug availability. Third, trials included in our analysis were open label and timing of 
randomization was not the same in all studies, which could dilute the difference between 
the S-DAPT and L-DAPT arms, especially if ischemic or bleeding events have occurred 
before randomization or DAPT discontinuation.  
 
CONCLUSIONS:  
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Compared to L-DAPT, S-DAPT was associated with significant increase in rate of ST in 
non-DM patients. Duration of DAPT had no significant impact on rates of all cause 
mortality, cardiac mortality, MI, ST and TVR among DM patients. 
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FIGURES LEGENDS: 
 
Figure 1 The Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) flow chart for the trial selection process 
Figure 2: Forest plot for stent thrombosis for DM and non-DM patients 
Figure 3: Forest plot for myocardial infarction for DM and non-DM patients 
Figure 4. Forest plot for all cause mortality for DM and non-DM patients  
Figure 5. Forest plot for cardiac mortality for DM and non-DM patients 
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Tables: 
Table 1. Baseline characteristics of studies included in analysis 
Table 2. Baseline patient characteristics in the studies included in the analysis 
Table 3. Outcomes with S-DAPT and L-DAPT in DM and non-DM patients 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
STUDY 
 
DESIGN 
 
Time to 
Randomizat
ion 
 
Inclusio
n 
Criteria 
 
Exclusion 
Criteria 
 
Primary 
end-point 
 
 
 
 
RESET 
 
(2012) 
 
 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
 
 
 
 
At index PCI 
 
 
20-85 
years 
old; 
≥50% 
stenosis; 
elective 
PCI; 
stable 
angina, 
unstable 
angina, 
or acute 
MI 
CI to anti-
platelets; 
STEMI within 
48 h; CVA; 
PAD; 
thromboemboli
sm; ST; ISR; 
CTO; LM 
stenosis>50%; 
History of DES 
Implantation; 
cardiogenic 
shock. 
 
 
 
Composite of 
Cardiac 
Death, MI, ST, 
ischemia-
driven TVR or 
Bleeding at 
12 Months 
after PCI 
 
 
 
 
OPTIMIZ
E 
 
(2014) 
 
 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
 
 
 
 
At index PCI 
 
Stable 
angina 
or silent 
ischemia 
or low 
risk ACS 
as 
defined 
by 
unstable 
angina 
or recent 
(but not 
acute) 
myocard
ial 
infarctio
n (<30 
days) 
 
STEMI for 
Primary or 
Rescue PCI; 
BMS less than 6 
months prior 
to index 
procedure; 
previous 
treatment with 
DES; scheduled 
surgery within 
12 months; CI 
to anti-
platelets; ISRs 
 
 
 
Composite of 
Death, MI, 
Stroke or 
Major 
Bleeding at 
12 Months 
after PCI 
 
 
 
ISAR-
SAFE 
 
(2014) 
 
 
Randomiz
ed, 
double-
blind, 
 
 
6 months 
after Index 
PCI 
 
 
Patients 
on 
clopidog
rel at 6 
 
Previous ST; 
DES in LM; MI 
in the previous 
6 months; 
Planned major 
 
Composite of 
Death, MI, 
Stroke 
or ST 
or TIMI major 
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multicentr
e 
 
(−1/+2) 
months 
after PCI 
with DES 
 
 
surgery within 
next 6 months; 
CI to anti-
platelets; OAC; 
Prior ICH 
 
 
Bleeding at 
15 
Months after 
PCI 
 
 
 
 
 
EXCELLE
NT 
 
(2012) 
 
 
 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
 
 
 
 
At index PCI 
 
≥1 lesion 
native 
coronary 
vessel; 
>50% 
stenosis; 
stable 
angina, 
unstable 
angina, 
recent 
MI, silent 
ischemia, 
positive 
function
al study, 
or 
reversibl
e 
changes 
on ECG 
consiste
nt with 
ischemia 
 
 
MI within 72 
hours; any 
prior stent 
implanted in 
the target 
vessel; 
cardiogenic 
shock; 
major bleeding 
within 3 
months; 
elective 
surgical 
procedure 
within 12 
months; left 
main stenosis > 
50%; CTOs; 
bifurcation 
lesions 
requiring 2-
stent strategy. 
 
 
 
 
 
Composite of 
Cardiac 
Death, MI or 
TVR at 12 
Months after 
PCI 
 
 
 
 
OPTIDUA
L 
 
(2015) 
 
 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
 
 
12 months 
after index 
PCI 
 
Stable 
angina, 
silent 
ischaemi
a, or 
acute 
coronary 
syndrom
e  
with ≥1 
lesion 
 
Requirement 
for oral 
anticoagulation
, 
DES 
implantation in 
an unprotected 
left main 
coronary 
artery, 
and 
 
Composite of 
all-cause 
mortality, 
non-fatal 
myocardial 
infarction, 
stroke, 
or major 
bleeding.  
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with 
stenosis 
>50% 
located 
in a 
native 
vessel 
implante
d with 
≥1 DES 
of any 
type. 
malignancies 
or other 
coexisting 
conditions 
associated with 
a life 
expectancy of 
<2 years 
 
 
 
 
 
ARCTIC 
 
(2014) 
 
 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
 
 
12 months 
after index 
PCI 
 
 
 
≥18 
years 
and 
eligible 
for PCI 
with 
planned 
use of ≥1 
DES. 
 
Primary PCI for 
STEMI; chronic 
anticoagulation 
or bleeding 
diathesis; CI to 
APT; active 
bleeding or 
major surgery 
within 3 
months; 
scheduled 
surgery within 
1 year 
 
 
 
 
Composite of 
Death, MI, 
Stroke or TIA, 
urgent 
revascularizat
ion or ST 
 
DES-
LATE 
 
(2014) 
 
Randomiz
ed, open 
label, 
multicentr
e 
 
12 months 
after index 
PCI 
DES 
within 
12 
months; 
on DAPT; 
no MACE 
(MI, 
stroke, 
repeat 
PCI) or 
major 
bleeding 
since 
PCI. 
CI to 
antiplatelet 
drugs, 
concomitant 
vascular 
disease  or 
recent ACS 
requiring 
clopidogrel use 
 
Composite of 
Cardiac 
Death, MI or 
Stroke at 24 
Months after 
PCI 
 
 
DAPT 
 
 
Randomiz
 
 
12 months 
 
 
>18 
 
Planned major 
surgery within 
 
ST; 
Composite of 
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(2014) 
 
ed, 
double-
blind, 
multicentr
e 
after index 
PCI 
years 
undergoi
ng FDA-
approve
d PCI 
with DES 
or BMS; 
No MACE  
or 
bleeding 
within 
12 
months 
after 
procedur
e. 
the 30 months 
post 
enrollment; 
OAC; Both BMS 
and DES during 
index 
procedure; PCI 
or surgery 
between 6 
weeks post-PCI 
and 
randomization 
death, MI, 
stroke; and 
Moderate or 
severe 
GUSTO 
bleeding 
 
Table 1. Baseline characteristics of studies included in analysis 
 
ACS: Acute coronary syndrome, BMS: bare metal stent, CI: contraindication; CKD: 
Chronic kidney disease, CTO: Chronic total occlusion, ECG: Electrocardiogram, FDA: 
Food and Drug Administration, LM: Left main, TVR: target vessel revascularization, 
STEMI: ST segment elevation myocardial infarction, NSTEMI: non ST segment 
elevation myocardial infarction, PCI: Percutaneous coronary interventions, MI: 
myocardial infarction, DES, drug eluting stents, OAC: oral anticoagulant, MACE: major 
adverse cardiac event, GUSTO: Global Utilization Of Streptokinase And Tpa For 
Occluded Arteries, SVG: Saphenous venous grafts, UPLMA: Unprotected left main 
artery. 
 
ARCTIC: Assessment by a double Randomisation of a Conventional antiplatelet strategy 
versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment 
Interruption versus Continuation 1 year after stenting; DAPT: The dual antiplatelet 
therapy study; DES-LATE: the Optimal Duration of Clopidogrel Therapy With DES to 
Reduce Late Coronary Arterial Thrombotic Event; EXCELLENT: Efficacy of 
Xience/Promus Versus Cypher in rEducing Late Loss After stENTing; ISAR-SAFE: 
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting 
Stenting; OPTIDUAL: Optimal Duration of Dual Antiplatelet Therapy After Drug-
eluting Stent Implantation; OPTIMIZE: Optimized Duration of Clopidogrel Therapy 
Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical 
Practice; RESET: REal Safety and Efficacy of 3-month dual antiplatelet Therapy 
following Endeavor zotarolimus-eluting stent implantation). 
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Study 
 
 
 
N 
Tot
al 
 
 
 
N 
DM 
 
 
 
N 
Non-
DM 
 
Follow
-up 
(mont
hs) 
 
 
 
Ag
e 
(y
) 
 
 
 
Ma
le 
(%
) 
 
 
HT
N 
(%
) 
 
 
HL
D 
(%
) 
 
 
Pri
or 
MI 
(%) 
 
 
 
AC
S 
(
%
) 
 
 
2nd 
gen 
ste
nt 
(%
) 
 
 
RESET 
 
 
211
7 
3 
month
s= 
146 
 
12 
month
s= 
146 
 
 
3 
months
= 913 
 
12 
months
= 
912 
 
 
12 
 
 
62 
 
 
64 
 
 
62 
 
 
59 
 
 
2 
 
 
28 
 
 
85 
 
 
OPTIMIZ
E 
 
 
311
9 
3 
month
s= 
554 
 
12 
month
s= 
549 
 
 
3 
months
= 1009 
 
12mont
hs= 
1007 
 
 
12 
 
 
62 
 
 
63 
 
 
87 
 
 
64 
 
 
35 
 
 
32 
 
 
100 
 
 
ISAR-
SAFE 
 
 
399
7 
6 
month
s= 
495 
 
12 
month
s= 
484 
 
 
6 
months
= 
1501 
 
12 
months
= 
1517 
 
 
9 
 
 
67 
 
 
81 
 
 
90 
 
 
87 
 
 
25 
 
 
40 
 
 
89 
 
 
EXCELL
ENT 
 
 
144
3 
6 
month
s= 
272 
6 
months
= 450 
 
 
 
12 
 
 
63 
 
 
65 
 
 
73 
 
 
76 
 
 
5 
 
 
51 
 
 
75 
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12 
month
s= 
278 
 
 
12mont
hs= 
443 
 
 
ARCTIC 
 
 
125
9 
12 
month
s= 
222 
 
18 
month
s= 
198 
 
 
12 
months
= 
402 
 
18 
months
= 
437 
 
 
17 
 
 
64 
 
 
80 
 
 
60 
 
 
67 
 
 
30 
 
 
26 
 
 
63 
 
 
DES-
LATE 
 
 
504
5 
12 
month
s= 
709 
 
30 
month
s= 
709 
 
 
12 
months
= 
1805 
 
30 
months
= 1822 
 
 
24 
 
 
62 
 
 
69 
 
 
57 
 
 
NA 
 
 
4 
 
 
61 
 
 
36 
 
 
      DAPT 
 
 
996
1 
12 
month
s= 
1481 
 
30 
month
s= 
1556 
 
 
12 
months
= 
3460 
 
30 
months
= 3464 
 
 
18 
 
 
62 
 
 
75 
 
 
75 
 
 
NA 
 
 
22 
 
 
26 
 
 
61 
 
 
OPTIDU
AL 
 
 
 
138
5 
12 
month
s= 
222 
 
12 
months
= 468 
 
48 
 
 
33 
 
 
64 
 
 
81 
 
 
59 
 
 
NA 
 
 
17 
 
 
36 
 
 
66 
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48 
month
s= 
213 
months
= 
482 
Table 2. Baseline patient characteristics in the studies included in the analysis 
%: percent; ACS: Acute coronary syndrome, N: Number of patients, DM: diabetes 
mellitus, MI: myocardial infarction, HTN: hypertension, HLD: hyperlipidemia 
 
 
ARCTIC: Assessment by a double Randomisation of a Conventional antiplatelet strategy 
versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment 
Interruption versus Continuation 1 year after stenting; DAPT: The dual antiplatelet 
therapy study; DES-LATE: the Optimal Duration of Clopidogrel Therapy With DES to 
Reduce Late Coronary Arterial Thrombotic Event; EXCELLENT: Efficacy of 
Xience/Promus Versus Cypher in rEducing Late Loss After stENTing; ISAR-SAFE: 
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting 
Stenting; OPTIDUAL: Optimal Duration of Dual Antiplatelet Therapy After Drug-
eluting Stent Implantation; OPTIMIZE: Optimized Duration of Clopidogrel Therapy 
Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical 
Practice; RESET: REal Safety and Efficacy of 3-month dual antiplatelet Therapy 
following Endeavor zotarolimus-eluting stent implantation). 
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 All patients 
(N=28,318) 
Diabetics 
(N=8,234) 
Non- 
Diabetics 
(N=20,084) 
Pinteraction Hetero-
geneity 
(I2) 
All cause 
mortality 
 
1.04 [0.74, 
1.46] 
1.19 [0.72-
1.95] 
 
0.93 [0.58, 
1.48] 
0.48 0% 
Cardiac 
mortality 
 
0.97 [0.64, 
1.46] 
1.25 [0.69, 
2.25] 
0.75 [0.42, 
1.35] 
0.23 0% 
MI 
 
1.48 [1.00, 
2.19] 
1.33 [0.88, 
2.01] 
1.52 [0.81, 
2.83] 
0.73 58% 
ST 
 
2.16 [1.21, 
3.85] 
1.52 [0.70, 
3.29] 
3.67 [2.04, 
6.59] 
0.07 21% 
TVR 
 
1.12 [0.85, 
1.47] 
1.39 [0.89, 
2.17] 
0.99 [0.71, 
1.39] 
0.24 20% 
Major bleeding* 
 
0.77 [0.34, 
1.72] 
0.92 [0.19, 
4.42] 
0.72 [0.28, 
1.84] 
0.79 0% 
Stroke 
 
1.00 [0.48, 
2.09] 
0.98[0.29, 
3.28] 
1.01 [0.40, 
2.56] 
0.98 0% 
NACE 
 
0.97 [0.76, 
1.25] 
0.94 [0.57, 
1.54] 
1.01 [0.77, 
1.32] 
0.81 48% 
S-DAPT compared with L-DAPT in diabetics and non-diabetics; *: GUSTO or TIMI 
major bleeding 
 
MI: myocardial infarction; NACE: net adverse clinical events; ST: Stent thrombosis (definite or 
probable); TVR: target vessel revascularization 
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